Interleukines in blood serum of patients with bone tumors

И.В. Бабкина; Ю.С. Тимофеев; И.Н. Кузнецов; Д.В. Рогожин; Е.Ю. Руссо; З.Г. Кадагидзе; Ю.Н. Соловьев

Interleukines in blood serum of patients with bone tumors

И.В. Бабкина¹, Ю.С. Тимофеев², И.Н. Кузнецов³, Д.В. Рогожин⁴, Е.Ю. Руссо⁵, З.Г. Кадагидзе⁶, Ю.Н. Соловьев⁷

research article Pages: 23-28

^1,6 д.м.н., профессор, кафедра клинической биохимии и лабораторной диагностики, Московский государственный медико-стоматологический университет им. А.И. Евдокимова
² врач клинической лабораторной диагностики, лаборатория клинической биохимии, Российский онкологический научный центр им. Н.Н. Блохина РАМН (Москва)
³ к.б.н., ст. лаборант, кафедра клинической биохимии и лабораторной диагностики, Московский государственный медико-стоматологический университет им. А.И. Евдокимова
⁴ к.м.н., зав. патологоанатомическим отделением, ФГБУ «Российская детская клиническая больница» (Москва)
⁵ соискатель, кафедра клинической биохимии и лабораторной диагностики, Московский государственный медико-стоматологический университет им. А.И.Евдокимова
⁷ д.м.н., профессор, академик РАН, гл. науч. сотрудник, отдел патологической анатомии опухолей человека, Российский онкологический научный центр им. Н.Н. Блохина РАМН (Москва)

Keywords: IL-16 IL-2 bone tumors

Abstract

Progress in the treatment of cancer and bone tumors including associated with a significant breakthrough in molecular biology, immunology, understanding the causes of tumor cells and patterns of development of the tumor process. The results of studies of interleukins (IL-16, IL-2) by ELISA in the serum of patients with primary malignant bone tumors and healthy age-matched to identify the possible correlation with the histological structure of the tumor. It is shown that the detection rate of IL-16 in serum in bone tumors was 93%, no significant differences in levels of IL-16 in considering the histological structure of tumor is not revealed. Relationship between the size of the primary tumor and the content of IL-16 in serum were found. Overall 3- and 5-year survival of patients with malignant bone tumors with IL-16 content in the blood serum of >33.0 pg/ml was significantly lower than patients with low levels of IL-16. Osteosarcoma overall 5-year survival in patients with high IL-16 in serum was 1.6 times, Ewing's sarcoma in 1.7 times, chondrosarcoma - 1.8 times lower than in patients with IL-16 content serum <33.0 pg/ml. IL-2 serum samples of healthy subjects was absent in all bone tumors in 1 patient (1.4%) without concomitant pathology revealed significant level of IL-2.

How to cite

Бабкина И.В., Тимофеев Ю.С., Кузнецов И.Н., Рогожин Д.В., Руссо Е.Ю., Кадагидзе З.Г., Соловьев Ю.Н. Интерлейкины в сыворотке крови больных новообразованиями костей // Вопросы биологической, медицинской и фармацевтической химии. 2014. № 8. С. 23–28.

References

Berezhnaya N.M., Chexun V.F. Immunologiya zlokachestvennogo rosta // Kiev: Naukova dumka. 2005. 790 s.
Lebedev K.A., Ponyakina I.D. Immunnaya nedostatochnost' (vy'yavlenie i lechenie) // M.: Mediczinskaya kniga. N.Novgorod: Izdatel'stvo NGMA. 2003. 443s.
Anderson P. Non-surgical treatment of pulmonary and extra-pulmonary metastases // Cancer Treat. Res. 2009. V. 152. P. 203 - 215.
Atanackovic D., Hildebrandt Y., Templin J. et al. Role of interleukin 16 in multiple myeloma // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 1005 - 1020.
Cao Y., Luetkens T., Kobold S. et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients // Exp. Hematol. 2010. V. 38. № 10. P. 860 - 867.
Compérat E., Rouprêt M., Drouin S.J. et al. Tissue expression of IL-16 in prostate cancer and its association with recurrence after radical prostatectomy // Prostate. 2010. V. 70. № 15. P. 1622 - 1627.
Fagioli F., Biasin E., Mereuta O.M. et al. Poor prognosis osteosarcoma: new therapeutic approach // Bone Marrow Transplant. 2008. V. 41. Suppl. 2. S. 131 - 134.
Gao L.B., Liang W.B., Xue H. et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma // Clin. Chim. Acta. 2009. V. 409. № 1 - 2. P. 132 - 135.
Gao L.B., Rao L., Wang Y.Y. et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer // Carcinogenesis. 2009. V. 2. № 2. P. 295 - 299.
Hamblin A.S. Lymphokines and interleukins // Immunology. 1988. S.1. P. 39 - 41.
Kohyama K., Sugiura H., Kozawa E. et al. Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model // Anticancer Res. 2012. V. 32. № 3. P. 779 - 782.
Koike M., Sekigawa I., Okada M. et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16 // Leuk. Res. 2002. V. 26. P. 705 - 711.
Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy // Biomed. Pharmacother. 2001. V. 55. P. 111 - 116.
Li S., Deng Y., Chen Z.P. et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population // Infect. Genet. Evol. 2011. V. 11. № 8. P. 2083 - 2088.
Mackall C.L., Rhee E.H., Read E.J. et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas // Clin. Cancer Res. 2008. V. 14. № 15. P. 4850 - 4858.
Mahindra A., Anderson K.C. Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target - // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 964-965.
Markiewicz K., Zeman K., Kozar A., Gołebiowska-Wawrzyniak M. Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report // Med. Wieku Rozwoj. 2011. V. 15. № 1. P. 25 - 31.
Mathy N.L., Scheuer W., Lanzendörfer M. et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes // Immunology. 2000. V. 100. P. 63 - 69.
Mc Tiernan A., Jinks R.C., Sydes M.R. et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup // Eur. J. Cancer. 2012. V. 48. № 5. P. 703 - 712.
Moon M.H., Jeong J.K., Seo J.S. et al. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation // Exp. Mol. Med. 2011. V. 43. № 3. P. 138 - 145.
Rumsaeng V., Cruikshank W.W., Foster B. et al. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16 // J. Immunol. 1997. V. 159. P. 2904 - 2910.
Sharma V., Sparks J.L., Vail J.D. Human B-cell lines constitutively express and secrete interleukin-16 // Immunology. 2000. V. 99. P. 266 - 271.
Thomas G., Jacobs K.B., Yeager M. et al. Multiple loci identified in a genome-wide association study of prostate cancer // Nat. Genet. 2008. V. 40. P. 310 - 315.
Waldmann T.A. Multichain interleukin-2 receptor: a target for immunotherapy in limphoma // J. Natl. Cancer Inst. 1989. V. 81. № 12. P. 914 - 923.
Yellapa A., Bahr J.M., Bitterman P. et al. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer // Int. J. Gynecol. Cancer. 2012. V. 22. № 2. P. 199 - 207.
Zhu J., Qin C., Yan F. et al. IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population // Int. J. Urol. 2010. V. 17. № 8. P. 700 - 707.

[1] Berezhnaya N.M., Chexun V.F. Immunologiya zlokachestvennogo rosta // Kiev: Naukova dumka. 2005. 790 s.

[2] Lebedev K.A., Ponyakina I.D. Immunnaya nedostatochnost' (vy'yavlenie i lechenie) // M.: Mediczinskaya kniga. N.Novgorod: Izdatel'stvo NGMA. 2003. 443s.

[3] Anderson P. Non-surgical treatment of pulmonary and extra-pulmonary metastases // Cancer Treat. Res. 2009. V. 152. P. 203 - 215.

[4] Atanackovic D., Hildebrandt Y., Templin J. et al. Role of interleukin 16 in multiple myeloma // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 1005 - 1020.

[5] Cao Y., Luetkens T., Kobold S. et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients // Exp. Hematol. 2010. V. 38. № 10. P. 860 - 867.

[6] Compérat E., Rouprêt M., Drouin S.J. et al. Tissue expression of IL-16 in prostate cancer and its association with recurrence after radical prostatectomy // Prostate. 2010. V. 70. № 15. P. 1622 - 1627.

[7] Fagioli F., Biasin E., Mereuta O.M. et al. Poor prognosis osteosarcoma: new therapeutic approach // Bone Marrow Transplant. 2008. V. 41. Suppl. 2. S. 131 - 134.

[8] Gao L.B., Liang W.B., Xue H. et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma // Clin. Chim. Acta. 2009. V. 409. № 1 - 2. P. 132 - 135.

[9] Gao L.B., Rao L., Wang Y.Y. et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer // Carcinogenesis. 2009. V. 2. № 2. P. 295 - 299.

[10] Hamblin A.S. Lymphokines and interleukins // Immunology. 1988. S.1. P. 39 - 41.

[11] Kohyama K., Sugiura H., Kozawa E. et al. Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model // Anticancer Res. 2012. V. 32. № 3. P. 779 - 782.

[12] Koike M., Sekigawa I., Okada M. et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16 // Leuk. Res. 2002. V. 26. P. 705 - 711.

[13] Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy // Biomed. Pharmacother. 2001. V. 55. P. 111 - 116.

[14] Li S., Deng Y., Chen Z.P. et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population // Infect. Genet. Evol. 2011. V. 11. № 8. P. 2083 - 2088.

[15] Mackall C.L., Rhee E.H., Read E.J. et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas // Clin. Cancer Res. 2008. V. 14. № 15. P. 4850 - 4858.

[16] Mahindra A., Anderson K.C. Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target - // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 964-965.

[17] Markiewicz K., Zeman K., Kozar A., Gołebiowska-Wawrzyniak M. Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report // Med. Wieku Rozwoj. 2011. V. 15. № 1. P. 25 - 31.

[18] Mathy N.L., Scheuer W., Lanzendörfer M. et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes // Immunology. 2000. V. 100. P. 63 - 69.

[19] Mc Tiernan A., Jinks R.C., Sydes M.R. et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup // Eur. J. Cancer. 2012. V. 48. № 5. P. 703 - 712.

[20] Moon M.H., Jeong J.K., Seo J.S. et al. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation // Exp. Mol. Med. 2011. V. 43. № 3. P. 138 - 145.

[21] Rumsaeng V., Cruikshank W.W., Foster B. et al. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16 // J. Immunol. 1997. V. 159. P. 2904 - 2910.

[22] Sharma V., Sparks J.L., Vail J.D. Human B-cell lines constitutively express and secrete interleukin-16 // Immunology. 2000. V. 99. P. 266 - 271.

[23] Thomas G., Jacobs K.B., Yeager M. et al. Multiple loci identified in a genome-wide association study of prostate cancer // Nat. Genet. 2008. V. 40. P. 310 - 315.

[24] Waldmann T.A. Multichain interleukin-2 receptor: a target for immunotherapy in limphoma // J. Natl. Cancer Inst. 1989. V. 81. № 12. P. 914 - 923.

[25] Yellapa A., Bahr J.M., Bitterman P. et al. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer // Int. J. Gynecol. Cancer. 2012. V. 22. № 2. P. 199 - 207.

[26] Zhu J., Qin C., Yan F. et al. IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population // Int. J. Urol. 2010. V. 17. № 8. P. 700 - 707.

Abstract

How to cite

Related articles